Evaluation of the relationship between circulating omentin-1 concentrations and components of the metabolic syndrome in adults without type 2 diabetes or cardiovascular disease

Diabetology & Metabolic Syndrome

Christina L Aquilante¹  Lisa A Kosmiski²  Brooke C Bredbeck¹  Maha S Sidhom¹  Anh Vu¹ 

[1] Department of Pharmaceutical Sciences, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, 12850 East Montview Boulevard, Mail Stop C238, Aurora, CO 80045 USA;Division of Endocrinology, Diabetes, and Metabolism, University of Colorado School of Medicine, Aurora, CO, USA

关键词: Sexual dimorphism;    Adipokine;    Metabolic syndrome;    Omentin-1;   

Others  :  812171
DOI  :  10.1186/1758-5996-6-4

 received in 2013-08-05, accepted in 2013-12-13,  发布年份 2014

【 摘 要 】

Background

Dysregulation of omentin-1, a beneficial adipokine, is thought to play a role in the development of type 2 diabetes and cardiovascular disease. The objective of this study was to evaluate the relationship between circulating omentin-1 concentrations and components of the metabolic syndrome in adults without type 2 diabetes or cardiovascular disease, and to determine if sex differences influenced the observed relationships.

Methods

Fasting blood samples were obtained from 93 adults, ages 30–60 years, without type 2 diabetes and/or cardiovascular disease. Participants were classified as having the metabolic syndrome according to American Heart Association/National Heart, Lung and Blood Institute criteria. Plasma omentin-1 concentrations were measured using a commercially-available enzyme-linked immunosorbent assay, and relationships between plasma omentin-1 and components of the metabolic syndrome were assessed in the entire study cohort, by metabolic syndrome status, and by sex.

Results

On average, participants were 48 ± 8 years of age, 50.5% were women, 54.8% were Caucasian, and 70% had the metabolic syndrome. Plasma omentin-1 concentrations did not differ significantly between individuals with versus without the metabolic syndrome (145.7 ± 70 versus 157.4 ± 79.3 ng/ml, p = 0.50). However, men with the metabolic syndrome had significantly lower omentin-1 levels than men without the metabolic syndrome (129.9 ± 66 versus 186.3 ± 84.3 ng/ml, p = 0.03). Plasma omentin-1 concentrations were significantly correlated with HDL cholesterol in the entire study cohort (r = 0.26; p = 0.01), which was primarily driven by a correlation in men (r = 0.451, p = 0.002) and participants with the metabolic syndrome (r = 0.36; p = 0.003). Plasma omentin-1 concentrations did not differ significantly between men and women; however men with the metabolic syndrome had 20% lower plasma omentin-1 levels than women with the metabolic syndrome (p = 0.06).

Conclusion

These data demonstrate that circulating omentin-1 levels are associated with HDL cholesterol, primarily in men and in the presence of the metabolic syndrome. In addition, sex appears to influence the relationship between plasma omentin-1 concentrations and components of the metabolic syndrome. Additional studies are needed to explore sexual dimorphism in circulating omentin-1 levels, and the role of omentin-1 in the metabolic syndrome.

【 授权许可】

   
2014 Vu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Schaffler A, Neumeier M, Herfarth H, Furst A, Scholmerich J, Buchler C: Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta 2005, 1732:96-102.
• [2]Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan JC, Gong DW: Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006, 290:E1253-1261.
• [3]Tan BK, Adya R, Randeva HS: Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med 2010, 20:143-148.
• [4]de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, Fried SK, Gong DW, Shuldiner AR, Pollin TI, McLenithan JC: Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007, 56:1655-1661.
• [5]Auguet T, Quintero Y, Riesco D, Morancho B, Terra X, Crescenti A, Broch M, Aguilar C, Olona M, Porras JA, Hernandez M, Sabench F, del Castillo D, Richart C: New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC Med Genet 2011, 12:60. BioMed Central Full Text
• [6]Pan HY, Guo L, Li Q: Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 2010, 88:29-33.
• [7]Tan BK, Adya R, Farhatullah S, Lewandowski KC, O'Hare P, Lehnert H, Randeva HS: Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008, 57:801-808.
• [8]Choi JH, Rhee EJ, Kim KH, Woo HY, Lee WY, Sung KC: Plasma omentin-1 levels are reduced in non-obese women with normal glucose tolerance and polycystic ovary syndrome. Eur J Endocrinol 2011, 165:789-796.
• [9]Tan BK, Pua S, Syed F, Lewandowski KC, O'Hare JP, Randeva HS: Decreased plasma omentin-1 levels in Type 1 diabetes mellitus. Diabet Med 2008, 25:1254-1255.
• [10]Yan P, Liu D, Long M, Ren Y, Pang J, Li R: Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2011, 119:257-263.
• [11]Moreno-Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, Fernandez-Real JM: Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity (Silver Spring) 2011, 19:1552-1559.
• [12]Shibata R, Ouchi N, Kikuchi R, Takahashi R, Takeshita K, Kataoka Y, Ohashi K, Ikeda N, Kihara S, Murohara T: Circulating omentin is associated with coronary artery disease in men. Atherosclerosis 2011, 219:811-814.
• [13]Liu R, Wang X, Bu P: Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract 2011, 93:21-25.
• [14]Shang FJ, Wang JP, Liu XT, Zheng QS, Xue YS, Wang B, Zhao LY: Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome. Biomarkers 2011, 16:657-662.
• [15]Yoo HJ, Hwang SY, Hong HC, Choi HY, Yang SJ, Seo JA, Kim SG, Kim NH, Choi KM, Choi DS, Baik SH: Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovasc Diabetol 2011, 10:103. BioMed Central Full Text
• [16]Zhong X, Zhang HY, Tan H, Zhou Y, Liu FL, Chen FQ, Shang DY: Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacol Sin 2011, 32:873-878.
• [17]Jialal I, Devaraj S, Kaur H, Adams-Huet B, Bremer AA: Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. J Clin Endocrinol Metab 2013, 98:E514-517.
• [18]Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome: an american heart association/national heart, lung, and blood institute scientific statement. Circulation 2005, 112:2735-2752.
• [19]Alberti KG, Zimmet P, Shaw J: The metabolic syndrome–a new worldwide definition. Lancet 2005, 366:1059-1062.
• [20]Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, Eckel RH: The metabolic syndrome. Endocr Rev 2008, 29:777-822.
• [21]Bremer AA, Devaraj S, Afify A, Jialal I: Adipose tissue dysregulation in patients with metabolic syndrome. J Clin Endocrinol Metab 2011, 96:E1782-1788.
• [22]Bremer AA, Jialal I: Adipose tissue dysfunction in nascent metabolic syndrome. J Obes 2013, 2013:393192.
• [23]Jialal I, Devaraj S, Adams-Huet B, Chen X, Kaur H: Increased cellular and circulating biomarkers of oxidative stress in nascent metabolic syndrome. J Clin Endocrinol Metab 2012, 97:E1844-1850.
• [24]Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
• [25]Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG: Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009, 42:377-381.
• [26]Greulich S, Chen WJ, Maxhera B, Rijzewijk LJ, van der Meer RW, Jonker JT, Mueller H, de Wiza DH, Floerke RR, Smiris K, Lamb HJ, de Roos A, Bax JJ, Romijn JA, Smit JW, Akhyari P, Lichtenberg A, Eckel J, Diamant M, Ouwens DM: Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies. PLoS One 2013, 8:e59697.
• [27]Rashid S, Watanabe T, Sakaue T, Lewis GF: Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 2003, 36:421-429.
• [28]Toth PP: Adiponectin and high-density lipoprotein: a metabolic association through thick and thin. Eur Heart J 2005, 26:1579-1581.
• [29]Turer AT, Scherer PE: Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012, 55:2319-2326.
• [30]Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730-1737.
• [31]Pischon T, Hu FB, Girman CJ, Rifai N, Manson JE, Rexrode KM, Rimm EB: Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women. Atherosclerosis 2011, 219:322-329.
• [32]Zhang H, Mo X, Hao Y, Huang J, Lu X, Cao J, Gu D: Adiponectin levels and risk of coronary heart disease: a meta-analysis of prospective studies. Am J Med Sci 2013, 345:455-461.
• [33]Shibata R, Ouchi N, Takahashi R, Terakura Y, Ohashi K, Ikeda N, Higuchi A, Terasaki H, Kihara S, Murohara T: Omentin as a novel biomarker of metabolic risk factors. Diabetol Metab Syndr 2012, 4:37. BioMed Central Full Text
• [34]Moreno-Navarrete JM, Catalan V, Ortega F, Gomez-Ambrosi J, Ricart W, Fruhbeck G, Fernandez-Real JM: Circulating omentin concentration increases after weight loss. Nutr Metab (Lond) 2010, 7:27. BioMed Central Full Text
• [35]Akbarzadeh S, Nabipour I, Assadi M, Movahed A, Jafari SM, Motamed N, Nazem H, Haraghy M, Pourbehi A, Bargahi A, Hajian N: The normoglycemic first-degree relatives of patients with type 2 diabetes mellitus have low circulating omentin-1 and adiponectin levels. Cytokine 2012, 58:295-299.
• [36]Luque-Ramirez M, Martinez-Garcia MA, Montes-Nieto R, Fernandez-Duran E, Insenser M, Alpanes M, Escobar-Morreale HF: Sexual dimorphism in adipose tissue function as evidenced by circulating adipokine concentrations in the fasting state and after an oral glucose challenge. Hum Reprod 2013, 28:1908-1918.
• [37]Martinez-Garcia MA, Montes-Nieto R, Fernandez-Duran E, Insenser M, Luque-Ramirez M, Escobar-Morreale HF: Evidence for masculinization of adipokine gene expression in visceral and subcutaneous adipose tissue of obese women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 2013, 98:E388-396.
• [38]Mahde A, Shaker M, Al-Mashhadani Z: Study of Omentin1 and other adipokines and hormones in PCOS patients. Oman Med J 2009, 24:108-118.
• [39]Tan BK, Adya R, Farhatullah S, Chen J, Lehnert H, Randeva HS: Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome. Diabetes 2010, 59:3023-3031.
• [40]Herder C, Karakas M, Koenig W: Biomarkers for the prediction of type 2 diabetes and cardiovascular disease. Clin Pharmacol Ther 2011, 90:52-66.